论文部分内容阅读
目的分析p62在宫颈癌和宫颈上皮内瘤变疾病中表达情况,旨在发现可以诊断宫颈癌和宫颈上皮内瘤生物因子。方法以67例宫颈浸润性癌,43例高级别上皮内病变(Ⅱ/Ⅲ),33例低级别上皮内病变(CINⅠ)患者及30例健康妇女的宫颈样本为研究对象。以免疫组化法监测测定研究对象宫颈样本内p62的表达情况。结果 p62在宫颈浸润性癌、CINⅡ/Ⅲ、CINⅠ及正常宫颈样本中的表达均差异具有统计学意义(P<0.05)。伴随宫颈部位病变的加重,p62的阳性率在不断升高。结论 p62的表达在宫颈浸润性癌、CINⅡ/Ⅲ、CINⅠ、正常宫颈表达情况均不相同,且随病情的加重表达量会随之增加,提示p62可作为诊断宫颈癌和宫颈上皮内瘤生物标志物。
Objective To analyze the expression of p62 in cervical cancer and cervical intraepithelial neoplasia, and to find out the biological factors that can diagnose cervical cancer and cervical intraepithelial neoplasia. Methods Cervical samples of 67 cases of invasive cervical cancer, 43 cases of high grade intraepithelial lesion (Ⅱ / Ⅲ), 33 cases of low grade intraepithelial lesion (CIN Ⅰ) and 30 healthy women were studied. Immunohistochemistry was used to detect the expression of p62 in cervical samples. Results The expression of p62 in invasive cervical carcinoma, CINⅡ / Ⅲ, CINⅠ and normal cervix was significantly different (P <0.05). Accompanied by cervical lesions, p62 positive rate is rising. Conclusions The expression of p62 in cervical invasive carcinoma, CINⅡ / Ⅲ, CINⅠ, normal cervix is different, and with the aggravation of the expression will increase, suggesting that p62 can be used as a diagnostic biomarkers of cervical cancer and cervical intraepithelial neoplasia Things.